ESTRO 2024 - Abstract Book

S749

Clinical - CNS

ESTRO 2024

Present Absent

30 (39) 41 (61)

Type of surgery at progression

GTR STR

15 (50) 15 (50)

Concurrent CHT

Present Absent

18 (23) 59 (67)

Type of concurrent CHT

Temozolomide Irinotecan + Bevacizumab

14 (78) 4 (22)

Radionecrosis after SRT

Present Absent

17 (22) 60 (78)

Conclusion:

Hypofractionated SRT is an effective treatment approach for patients with progressive glioblastoma. Patients progressed later than 14 months, received a ≥40 Gy EQD2 of SRT and experienced a pseudoprogression after SRT had improved survival rates.

Keywords: Glioblastoma, reirradiation, SRS

354

Digital Poster

Clinical outcome for Glioblastoma treated with photon radiotherapy in an MR-only workflow

Mattias Hedman 1,2 , Michael Gubanski 1,2 , Marcela Giovenco 1 , Fernanda Villegas Navarro 3,2

1 Karolinska University Hospital, Department of Radiation Oncology, Stockholm, Sweden. 2 Karolinska Institutet, Department of Oncology-Pathology, Stockholm, Sweden. 3 Karolinska University Hospital, Department of Medical Radiation Physics and Nuclear Medicine, Stockholm, Sweden

Purpose/Objective: